Interleukin 28B genotype determination using DNA from different sources: A simple and reliable tool for the epidemiological and clinical characterization of hepatitis C

Journal of Virological Methods

Volumn 178, Issue 1-2, 2011, Pages 235-238

  Cariani, Elisabetta ^a   Critelli, Rosina ^b   Rota, Cristina ^a   Luongo, Monica ^b   Trenti, Tommaso ^a   Villa, Erica ^b  

^a Ospedale Civile S Agostino Estense   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Formalin fixed paraffin embedded (FFPE) liver biopsy; Hepatitis C virus (HCV); IL28B; Interferon; Pharmacogenetics; Serum; Swab

Indexed keywords

INTERLEUKIN 28B;

ANTIVIRAL THERAPY; ARTICLE; BLOOD; CLINICAL RESEARCH; DIAGNOSTIC VALUE; DNA EXTRACTION; ETHNICITY; GENE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HUMAN; IL28B GENE; LIVER BIOPSY; MEDICAL HISTORY; ORAL BIOPSY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; SERUM; TREATMENT RESPONSE; VIRUS CHARACTERIZATION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HEPATITIS C; HUMANS; INTERLEUKINS; ITALY; MOLECULAR DIAGNOSTIC TECHNIQUES; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 80955158489     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.08.021     Document Type: Article

References (20)

1. Afdhal N.H., McHutchison J.G., Zeuzem S., Mangia A., Pawlotsky J.-M., Murray J.S., Shianna K.V., Tanaka Y., Thomas D.L., Booth D.R., Goldstein D.B. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53:336-345. for the Pharmacogenetics and Hepatitis C Meeting Participants.
2. Barrera J.M., Bruguera M., Ercilla M.G., Gil C., Celis R., Gil M.P., del Valle Onorato M., Rodés J., Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995, 21:639-644.
3. Charlton M., Pockros P.J., Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006, 43:1177-1186.
4. Fox B.A., Sheppard P.O., O'Hara P.J. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 2009, 4:e4933.
5. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
6. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 2004, 44:20-29. Global Burden of Hepatitis C Working Group.
7. Li M., Liu X., Zhou Y., Su S.B. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 2009, 86:23-32.
8. Montes-Cano M.A., García-Lozano J.R., Abad-Molina C., Romero-Gómez M., Barroso N., Aguilar-Reina J., Núñez-Roldán A., González-Escribano M.F. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
9. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J. Gastroenterol. 2006, 12:6756-6765.
10. Poynard T., McHutchison J., Goodman Z., Ling M.H., Albrecht J. Is an à la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000, 31:211-218.
11. Rallón N.I., Naggie S., Benito J.M., Medrano J., Restrepo C., Goldstein D., Shianna K.V., Vispo E., Thompson A., McHutchison J., Soriano V. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29.
12. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Günthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Müllhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.
13. Roffi L., Colloredo G., Pioltelli P., Bellati G., Pozzi M., Parravicini P., Bellia V., Del Poggio P., Fornaciari G., Ceriani R., Ramella G., Corradi C., Rossini A., Bruno S. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir. Ther. 2008, 13:663-673. Gruppo Epatologico Lombardo.
14. Stättermayer A.F., Stauber R., Hofer H., Rutter K., Beinhardt S., Scherzer T.M., Zinober K., Datz C., Maieron A., Dulic-Lakovic E., Kessler H.H., Steindl-Munda P., Strasser M., Krall C., Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011, 9:344-350.
15. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
16. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
17. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
18. Villa E., Karampatou A., Cammà C., Di Leo A., Luongo M., Ferrari A., Petta S., Losi L., Taliani G., Trande P., Lei B., Graziosi A., Bernabucci V., Critelli R., Pazienza P., Rendina M., Antonelli A., Francavilla A. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011, 140:818-829.
19. Witte K., Witte E., Sabat R., Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010, 21:237-251.
20. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5:610-622.